Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek Raghavan

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Cancer|April 3, 2008
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)A Oliver Sartor, Catherine M Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerJohann S de Bono, Howard I Scher, R Bruce Montgomery, et al.
Translational Andrology and Urology|March 14, 2023
Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancerJason Zhu, Chad Livasy, Erin E Donahue, et al.
Therapeutic Advances in Medical Oncology|November 19, 2010
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCERTanya B Dorff, Cathy M Tangen, E David Crawford, et al.
The Oncologist|November 28, 2019
Initial Results from Mobile Low-Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved PopulationsDerek Raghavan, Mellisa Wheeler, Darcy Doege, et al.
JCO Oncology Practice|November 18, 2024
Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical PracticeNilanjan Ghosh, Ashley Matusz-Fisher, Rupali Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusWalter M Stadler, Seth P Lerner, Susan Groshen, et al.
Clinical Genitourinary Cancer|February 4, 2025
Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II TrialEarle F Burgess, Claud M Grigg, Danielle Boselli, et al.
The New England Journal of Medicine|August 29, 2003
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerH Barton Grossman, Ronald B Natale, Catherine M Tangen, et al.
JCO Clinical Cancer Informatics|July 15, 2022
Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved PatientsCarol J Farhangfar, Gregory T Scarola, Victoria A Morris, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Cancer|April 3, 2008
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)A Oliver Sartor, Catherine M Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerJohann S de Bono, Howard I Scher, R Bruce Montgomery, et al.
Translational Andrology and Urology|March 14, 2023
Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancerJason Zhu, Chad Livasy, Erin E Donahue, et al.
Therapeutic Advances in Medical Oncology|November 19, 2010
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCERTanya B Dorff, Cathy M Tangen, E David Crawford, et al.
The Oncologist|November 28, 2019
Initial Results from Mobile Low-Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved PopulationsDerek Raghavan, Mellisa Wheeler, Darcy Doege, et al.
JCO Oncology Practice|November 18, 2024
Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical PracticeNilanjan Ghosh, Ashley Matusz-Fisher, Rupali Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusWalter M Stadler, Seth P Lerner, Susan Groshen, et al.
Clinical Genitourinary Cancer|February 4, 2025
Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II TrialEarle F Burgess, Claud M Grigg, Danielle Boselli, et al.
The New England Journal of Medicine|August 29, 2003
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerH Barton Grossman, Ronald B Natale, Catherine M Tangen, et al.
JCO Clinical Cancer Informatics|July 15, 2022
Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved PatientsCarol J Farhangfar, Gregory T Scarola, Victoria A Morris, et al.
Pageof 13